Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01068600 · ClinicalTrials.gov registry record · Phase 3
Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 318
- Enrollment target
NCT01068600: Completed Phase 3 study, sponsored by Novartis.
NCT01068600 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 318 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01068600, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 318 participants
- Enrollment target
Study Summary
This 12-week study evaluated the efficacy and safety of indacaterol versus placebo.
Primary Outcome
Spirometry was conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 hour 10 minute and 23 hour 45 minute post-dose FEV1 readings. Mixed model used baseline FEV1, FEV1 prior to and 10-15 minutes post inhalation of albuterol, and FEV1 prior to and 50-70 minutes post inhalation of ipratropium as covariates.
Interventions
- DRUG Placebo to indacaterol
- DRUG Indacaterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 318 participants |
| Start Date | 2010-01 |
| Phase | Phase 3 |
What the finished NCT01068600 record still lists
NCT01068600 is an interventional study that assigns participants to a tested intervention. The registered 318 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo to indacaterol is the first listed.
NCT01068600 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01068600 about?
NCT01068600 is a clinical study titled "Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks". This 12-week study evaluated the efficacy and safety of indacaterol versus placebo.
What is the current status of trial NCT01068600?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 318 participants. The study started on 2010-01.
What interventions are being tested in trial NCT01068600?
The interventions under investigation include: Placebo to indacaterol (DRUG), Indacaterol (DRUG).
Who is sponsoring clinical trial NCT01068600?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01068600's enrollment target sits among peer trials
318 1087th of 2000 higher than 912 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05488340 · 318 participants · Phase 2
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
- NCT05675735 · 318 participants · NA
Leveraging Regulatory Flexibility for Methadone Take-Home Dosing to Improve Retention in Treatment for Opioid Use Disorder
- NCT05895786 · 318 participants · Phase 3
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
- NCT06051617 · 318 participants · Phase 3
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia